In keeping with media reviews, Peak XV Companions Investments VI, Sequoia Capital International Progress Fund III and Redwood Belief reportedly supplied about 8.9 million shares at Rs 450 apiece, with Jefferies performing as the only bookrunner. The Financial Occasions couldn’t independently confirm the patrons and sellers within the transaction.
As of the June quarter, promoter entities held a 35.47% stake within the firm, whereas public shareholders owned the remaining 64.53%, in keeping with inventory trade knowledge. Amongst public shareholders, Peak XV Companions Investments VI held a 14.8% stake, whereas Sequoia Capital International Progress Fund III – US/India held a 3.44% stake.
Honasa Client Q1 outcomes
In Q1 FY27, the corporate reported its highest-ever consolidated revenue after tax (PAT) of Rs 90 crore, up 116.5% year-on-year (YoY).
Income from operations additionally hit a file Rs 756 crore, marking a 27% YoY enhance from Rs 595 crore in Q1 FY26. Earnings earlier than curiosity, taxes, depreciation and amortisation (EBITDA) surged 140.7% YoY to Rs 110 crore from Rs 46 crore, whereas the EBITDA margin expanded to 14.6% from 7.7% within the year-ago interval.
Honasa Client outlook
The corporate has set a income goal of Rs 5,500 crore by FY31, implying a CAGR of about 18% between FY26 and FY31. Mamaearth is predicted to stay the important thing development driver, with income projected to cross Rs 2,000 crore by FY31, whereas The Derma Co is predicted to contribute practically Rs 1,500 crore.
The corporate additionally plans to construct a minimum of two extra manufacturers with income of Rs 500 crore every throughout its portfolio, in keeping with an investor presentation. Its different manufacturers embrace Aqualogica, BBlunt, Dr Sheth’s and Reginald Males.Honasa goals to broaden its EBITDA margin to fifteen% by attaining a 500-basis-point enchancment via a stronger presence in higher-margin channels and classes, together with advantages from scale and working efficiencies.
Disclaimer: This text has been written by Veer Sharma, who is just not a SEBI-registered Analysis Analyst or an Funding Adviser. Veer Sharma and his ‘relative(s)’ (as outlined underneath Part 2(77) of the Corporations Act, 2013) don’t maintain any monetary curiosity within the corporations talked about on this article as of the date of publication. The views/suggestions talked about on this article, wherever relevant, are these of the respective SEBI-registered Analysis Analyst/brokerage and have been reproduced/reported with due attribution. They shouldn’t be construed because the views or suggestions of The Financial Occasions Digital or the journalist. Readers are suggested to contemplate the unique analysis report and make their funding choices based mostly on their very own evaluation. Brokerage disclaimers right here.